American International Group’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-65,341
| Closed | -$351K | – | 1263 |
|
|
2024
Q1 | $351K | Sell |
65,341
-561
| -0.9% | -$2.54K | ﹤0.01% | 1843 |
|
|
2023
Q4 | $331K | Buy |
65,902
+9,043
| +16% | +$28.4K | ﹤0.01% | 1888 |
|
|
2023
Q3 | $96.1K | Buy |
56,859
+3,795
| +7% | +$7.62K | ﹤0.01% | 2537 |
|
|
2023
Q2 | $148K | Buy |
53,064
+13,557
| +34% | +$38.3K | ﹤0.01% | 2343 |
|
|
2023
Q1 | $71.9K | Buy |
39,507
+786
| +2% | +$2.44K | ﹤0.01% | 2603 |
|
|
2022
Q4 | $196K | Sell |
38,721
-141
| -0.4% | -$774 | ﹤0.01% | 2135 |
|
|
2022
Q3 | $193K | Buy |
38,862
+548
| +1% | +$2.5K | ﹤0.01% | 2178 |
|
|
2022
Q2 | $143K | Buy |
38,314
+3,831
| +11% | +$15.4K | ﹤0.01% | 2385 |
|
|
2022
Q1 | $193K | Sell |
34,483
-1,811
| -5% | -$11.1K | ﹤0.01% | 2260 |
|
|
2021
Q4 | $221K | Sell |
36,294
-1,085
| -3% | -$8.15K | ﹤0.01% | 2308 |
|
|
2021
Q3 | $364K | Sell |
37,379
-96
| -0.3% | -$1.06K | ﹤0.01% | 2053 |
|
|
2021
Q2 | $535 | Buy |
37,475
+19,104
| +104% | +$316K | ﹤0.01% | 1880 |
|
|
2021
Q1 | $436 | Buy |
18,371
+48
| +0.3% | +$1.24K | ﹤0.01% | 1908 |
|
|
2020
Q4 | $244 | Sell |
18,323
-525
| -3% | -$5.05K | ﹤0.01% | 2178 |
|
|
2020
Q3 | $131K | Buy |
18,848
+1,263
| +7% | +$12.6K | ﹤0.01% | 2375 |
|
|
2020
Q2 | $216K | Buy |
+17,585
| New | +$99.3K | ﹤0.01% | 2073 |
|
|
2019
Q2 | – | Sell |
-17,983
| Closed | -$28K | – | 3132 |
|
|
2019
Q1 | $28K | Sell |
17,983
-584
| -3% | -$733 | ﹤0.01% | 2966 |
|
|
2018
Q4 | $22K | Sell |
18,567
-143
| -0.8% | -$327 | ﹤0.01% | 3016 |
|
|
2018
Q3 | $69K | Buy |
18,710
+597
| +3% | +$1.89K | ﹤0.01% | 2981 |
|
|
2018
Q2 | $55K | Sell |
18,113
-769
| -4% | -$2.85K | ﹤0.01% | 2972 |
|
|
2018
Q1 | $73K | Sell |
18,882
-1,015
| -5% | -$4.45K | ﹤0.01% | 2797 |
|
|
2017
Q4 | $89K | Sell |
19,897
-580
| -3% | -$2.75K | ﹤0.01% | 2780 |
|
|
2017
Q3 | $112K | Buy |
20,477
+1,532
| +8% | +$9.44K | ﹤0.01% | 2608 |
|
|
2017
Q2 | $144K | Buy |
18,945
+8,671
| +84% | +$37.5K | ﹤0.01% | 2483 |
|
|
2017
Q1 | $36K | Buy |
10,274
+688
| +7% | +$3.4K | ﹤0.01% | 2899 |
|
|
2016
Q4 | $55K | Sell |
9,586
-25
| -0.3% | -$167 | ﹤0.01% | 2834 |
|
|
2016
Q3 | $74.8K | Buy |
9,611
+14
| +0.1% | +$105 | ﹤0.01% | 2770 |
|
|
2016
Q2 | $59.7K | Buy |
9,597
+5,725
| +148% | +$44.4K | ﹤0.01% | 2899 |
|
|
2016
Q1 | $32K | Buy |
3,872
+2,872
| +287% | +$27.1K | ﹤0.01% | 4103 |
|
|
2015
Q4 | $17K | Hold |
1,000
| – | – | ﹤0.01% | 4341 |
|
|
2015
Q3 | $11K | Buy |
+1,000
| New | +$21.8K | ﹤0.01% | 4473 |
|
Other funds holding IBRX
American International Group's IBRX Position: Q2 2024 in Review
American International Group sold out of ImmunityBio (IBRX) in Q2 2024, closing a stake of 65,341 shares — an estimated $351K sold.
American International Group first reported a position in IBRX in Q3 2015 and held it in 31 quarters. The position peaked at $364K in Q3 2021. 193 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.
- American International Group reported no remaining ImmunityBio position as of Q2 2024 after selling out during the quarter.
- American International Group sold 65,341 ImmunityBio shares in Q2 2024, an estimated $351K.
- American International Group first reported a position in ImmunityBio in Q3 2015 and held it in 31 quarters.
- American International Group's ImmunityBio position peaked at $364K in Q3 2021.
- 193 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.
Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.